KALV

KalVista Pharmaceuticals, Inc. [KALV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KALV Stock Summary

Top 10 Correlated ETFs

KALV


Top 10 Correlated Stocks

KALV


In the News

06:30 28 Mar 2024 KALV

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17. KalVista is a Silver-level sponsor of the meeting. The presentations are: Relationship Between Tim.

06:30 28 Mar 2024 KALV

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26. The following presentations will take place on Saturday,.

06:43 28 Mar 2024 KALV

KalVista meets main goals in late-stage trial for skin condition treatment

KalVista Pharmaceuticals said on Tuesday its therapy for a type of skin condition met the main goals in a late-stage trial.

03:21 28 Mar 2024 KALV

KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement

Results from phase 3 KONFIDENT trial, using sebetralstat for on-demand treatment of patients with HAE, expected early 2024. Upon primary endpoint of PGI-C score being met, NDA filing of sebetralstat for HAE expected 1st half of 2024; European and Japan filings expected later in 2024. Oral Factor XIIa inhibitor being advanced for patients with HAE; This could open door to target prophylactic HAE market.

11:51 28 Mar 2024 KALV

KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024

KalVista Pharma (NASDAQ: KALV ) just reported results for the second quarter of 2024. KalVista Pharma reported earnings per share of -80 cents.

10:31 28 Mar 2024 KALV

3 Micro-Cap Stocks That Could Be Moonshots

Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and under-capitalized companies, but these companies also have unique theses that should keep investors interested.

06:30 28 Mar 2024 KALV

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences: Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 3:00 p.m. EST Jefferies London Healthcare Conference on Thursday, November 16, 2023 at 9:.

06:30 28 Mar 2024 KALV

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13. The presentations are: Understanding Why H.

12:05 28 Mar 2024 KALV

KalVista's Sebetralstat: A Pill Worth Swallowing In HAE

KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and improved patient adherence. Financially, KalVista has a cash runway of about 14 months, but rising G&A costs raise concerns about capital efficiency. Given the statistically significant Phase 2 results, I speculate that the Phase 3 data, expected in Q4 2023, will likely be positive.

10:31 28 Mar 2024 KALV

Is it a Good Idea to Invest in KalVista (KALV) Stock Now?

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.

KALV Financial details

Company Rating
Neutral
Market Cap
499.93M
Income
-122.03M
Revenue
0
Book val./share
2.55
Cash/share
2.18
Dividend
-
Dividend %
-
Employees
118
Optionable
No
Shortable
Yes
Earnings
11 Mar 2024
P/E
-4.11
Forward P/E
-4.88
PEG
-1.53
P/S
-
P/B
3.86
P/C
5.46
P/FCF
-5.6
Quick Ratio
7.01
Current Ratio
7.25
Debt / Equity
0.08
LT Debt / Equity
0.07
-
-
EPS (TTM)
-3.55
EPS next Y
-2.44
EPS next Q
-0.69
EPS this Y
-4.29%
EPS next Y
-31.15%
EPS next 5Y
-130.8%
EPS last 5Y
14.2%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
5%
-
-
-
-
SMA20
-14.29%
SMA50
-7.69%
SMA100
50%
Inst Own
0.06%
Inst Trans
0%
ROA
-77%
ROE
-72%
ROC
-0.97%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
42.19M
Shs Float
27.55M
-
-
-
-
Target Price
38
52W Range
6.29-16.88
52W High
-25.56%
52W Low
+98.5%
RSI
35
Rel Volume
2.18
Avg Volume
802.64K
Volume
1.75M
Perf Week
-2.62%
Perf Month
-19.31%
Perf Quarter
25.9%
Perf Half Y
24.32%
-
-
-
-
Beta
0.902
-
-
Volatility
0.44%, 1.13%
Prev Close
7.59%
Price
11.91
Change
6.34%

KALV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-04-30

Metric History 2019-04-302020-04-302021-04-302022-04-30 2023-04-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.070.710.6600
Net income per share
-1.38-1.64-2.33-2.8-2.68
Operating cash flow per share
-2.41-2.53-1.58-3.19-2.7
Free cash flow per share
-2.48-2.54-1.58-3.23-2.74
Cash per share
6.683.8213.046.795.36
Book value per share
6.414.7213.477.565.77
Tangible book value per share
6.414.7213.477.565.77
Share holders equity per share
6.414.7213.477.565.77
Interest debt per share
-0.60.090.310.38-0.35
Market cap
346.86M193.64M476.79M311.54M247.39M
Enterprise value
314.91M179.49M432.11M289M199.39M
P/E ratio
-16.66-6.65-10.72-4.55-3.31
Price to sales ratio
21.5115.2637.5700
POCF ratio
-9.54-4.32-15.8-3.99-3.29
PFCF ratio
-9.26-4.3-15.76-3.94-3.24
P/B Ratio
3.592.311.851.681.54
PTB ratio
3.592.311.851.681.54
EV to sales
19.5314.1434.0500
Enterprise value over EBITDA
-10.68-4.53-7.42-3.06-1.81
EV to operating cash flow
-8.66-4.01-14.32-3.7-2.65
EV to free cash flow
-8.41-3.99-14.28-3.66-2.61
Earnings yield
-0.06-0.15-0.09-0.22-0.3
Free cash flow yield
-0.11-0.23-0.06-0.25-0.31
Debt to equity
00.020.020.040.05
Debt to assets
00.020.020.040.04
Net debt to EBITDA
1.080.360.770.240.44
Current ratio
6.411.4927.0416.7311.46
Interest coverage
3.2500-88.646.17
Income quality
1.751.540.650.950.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.681.031.3100
Research and developement to revenue
2.173.173.2500
Intangibles to total assets
00000
Capex to operating cash flow
0.03000.010.02
Capex to revenue
-0.07-0.02-0.0100
Capex to depreciation
-2.86-0.43-0.15-1.65-1.67
Stock based compensation to revenue
0.180.350.5600
Graham number
14.1113.226.5721.8318.67
ROIC
-0.31-0.46-0.21-0.4-0.5
Return on tangible assets
-0.18-0.31-0.16-0.34-0.41
Graham Net
5.834.0212.676.515.01
Working capital
97.49M80.98M254.49M182.07M157.29M
Tangible asset value
96.74M83.75M257.19M185.09M161.03M
Net current asset value
94.15M79.92M249.44M174.86M150.15M
Invested capital
00.020.020.040.05
Average receivables
9.07M13.92M13.47M12.26M15.33M
Average payables
2.15M2.27M1.83M2.81M4.23M
Average inventory
0001.35M1.35M
Days sales outstanding
256.09475.36299.6500
Days payables outstanding
29.81K15.23K1.11K1.79K2.19K
Days of inventory on hand
0001.33K0
Receivables turnover
1.430.771.2200
Payables turnover
0.010.020.330.20.17
Inventory turnover
0000.270
ROE
-0.22-0.35-0.17-0.37-0.46
Capex per share
-0.07-0.010-0.04-0.04

Quarterly Fundamentals Overview

Last date of statement is 2024-01-31 for Q3

Metric History 2023-01-312023-04-302023-07-312023-10-31 2024-01-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.51-1.17-0.74-0.8-0.84
Operating cash flow per share
-0.33-0.66-0.78-0.57-0.79
Free cash flow per share
-0.33-0.66-0.78-0.58-0.79
Cash per share
6.074.353.582.982.18
Book value per share
6.524.694.053.312.55
Tangible book value per share
6.524.694.053.312.55
Share holders equity per share
6.524.694.053.312.55
Interest debt per share
0.330.20.230.220.21
Market cap
225.1M304.62M347.58M293.46M547.59M
Enterprise value
148.53M256.61M306.16M243.49M531.98M
P/E ratio
-3.93-1.9-3.43-2.65-4.72
Price to sales ratio
00000
POCF ratio
-24.23-13.46-13-14.8-19.86
PFCF ratio
-24.19-13.42-13-14.65-19.85
P/B Ratio
1.221.892.492.566.18
PTB ratio
1.221.892.492.566.18
EV to sales
00000
Enterprise value over EBITDA
-5.39-8.05-10.43-8.62-16.15
EV to operating cash flow
-15.99-11.34-11.45-12.28-19.29
EV to free cash flow
-15.96-11.3-11.45-12.16-19.28
Earnings yield
-0.06-0.13-0.07-0.09-0.05
Free cash flow yield
-0.04-0.07-0.08-0.07-0.05
Debt to equity
0.050.050.060.070.08
Debt to assets
0.040.040.050.060.07
Net debt to EBITDA
2.781.511.411.770.47
Current ratio
16.5511.4610.67.255.44
Interest coverage
-36.8122.3000
Income quality
0.440.861.060.720.95
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0000.010
Capex to revenue
00000
Capex to depreciation
-0.08-0.37-0.03-1.04-0.09
Stock based compensation to revenue
00000
Graham number
8.6211.098.197.726.93
ROIC
-0.09-0.27-0.18-0.23-0.32
Return on tangible assets
-0.07-0.22-0.16-0.2-0.25
Graham Net
5.714.073.122.441.96
Working capital
180.53M157.29M135.71M110.86M84.98M
Tangible asset value
184.44M161.03M139.34M114.45M88.58M
Net current asset value
173.11M150.15M128.85M104.31M78.72M
Invested capital
0.050.050.060.070.08
Average receivables
16.91M14.23M18.57M20.93M22.49M
Average payables
2.54M3.26M4.94M4.98M4M
Average inventory
00-10.29M-20.93M-10.65M
Days sales outstanding
00000
Days payables outstanding
731.21.34K2.29K2.24K1.35K
Days of inventory on hand
00-9.3K-9.73K0
Receivables turnover
00000
Payables turnover
0.120.070.040.040.07
Inventory turnover
00-0.01-0.010
ROE
-0.08-0.25-0.18-0.24-0.33
Capex per share
000-0.010

KALV Frequently Asked Questions

What is KalVista Pharmaceuticals, Inc. stock symbol ?

KalVista Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol KALV

Is KalVista Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $38. The lowest prediction is $38 and the highest is $38

What is KALV stock prediction ?

What is KalVista Pharmaceuticals, Inc. stock quote today ?

KalVista Pharmaceuticals, Inc. stock price is $11.91 today.

Is KalVista Pharmaceuticals, Inc. stock public?

Yes, KalVista Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap